Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Patients who received atezolizumab (Tecentriq) plus bevacizumab (Avastin) had a 28% lower risk of cancer recurrence or death.
An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.
Treatment with Tecentriq plus Avastin or with Keytruda alone delays disease progression and improves survival.
The immunotherapy and targeted therapy combo improved both overall survival and patient-reported outcomes.
Tecentriq plus Avastin improved improved overall survival and patient experiences during treatment.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.